Compare Davita Inc (DVA) vs Ingersoll Rand (IR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Ingersoll Rand — how do they compare? Davita Inc trades at $183.86 (market cap $11.73B), while Ingersoll Rand trades at $71.83 (market cap $27.87B). The key difference: Ingersoll Rand is far larger — about 2.4× Davita Inc's market cap, and Ingersoll Rand pays a 0.11% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | IR | |
|---|---|---|
Market Cap | $11.73B | $27.87B |
Volume | 2,098,888 | 8,710,362 |
Sector | Health | Industrials |
52-Week High | $240.96 | $98.76 |
52-Week Low | $103.87 | $68.54 |
Typical Hold Time | 111 Days | — |
Enterprise Value | $24.45B | $31.53B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.86, up 0.42% today, showing resilience amid market volatility. The stock demonstrates strong fundamental performance with consistent earnings beats (Q4 2025-Q2 2026) and revenue growth from $11.6B in 2022 to $13.6B in 2025. Technical indicators show neutral momentum with RSI at 51.57, while analyst consensus remains positive with a $235.67 price target. Recent developments include expanded value-based care partnerships with Humana and significant institutional buying activity.
DVA presents a compelling investment case with attractive valuation (P/E 15.58, P/S 0.92) and strong profitability (ROE 635.3%). However, investors face risks from regulatory pressures, high debt levels (debt-to-asset ratio 65.55%), and margin compression. The stock's 22% upside to consensus target suggests potential, but requires monitoring of reimbursement trends and competitive dynamics in the healthcare sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →
